Chemical and Systems Biology, Chem-H, Stanford Cancer Institute, Stanford Medicine, Stanford University, Stanford, CA, USA.
Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA; Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Eur J Med Chem. 2022 Aug 5;238:114433. doi: 10.1016/j.ejmech.2022.114433. Epub 2022 May 8.
Cyclin-dependent kinases (CDK) are attractive targets for drug discovery due to their wide range of cellular functions. CDK11 is an understudied CDK with roles in transcription and splicing, cell cycle regulation, neuronal function, and apoptosis. In this study, we describe a medicinal chemistry campaign to identify a CDK11 inhibitor. Employing a promising but nonselective CDK11-targeting scaffold (JWD-047), extensive structure-guided medicinal chemistry modifications led to the identification of ZNL-05-044. A combination of biochemical evaluations and NanoBRET cellular assays for target engagement guided the SAR towards a 2,4-diaminothiazoles CDK11 probe with significantly improved kinome-wide selectivity over JWD-047. CDK11 inhibition with ZNL-05-044 leads to G2/M cell cycle arrest, consistent with prior work evaluating OTS964, and impacts CDK11-dependent mRNA splicing in cells. Together, ZNL-05-044 serves as a tool compound for further optimization and interrogation of the consequences of CDK11 inhibition.
细胞周期蛋白依赖性激酶(CDK)因其广泛的细胞功能而成为药物发现的有吸引力的靶点。CDK11 是一种研究较少的 CDK,其在转录和剪接、细胞周期调控、神经元功能和细胞凋亡中发挥作用。在这项研究中,我们描述了一项药物化学研究,以确定 CDK11 抑制剂。采用有前途但非选择性的 CDK11 靶向支架(JWD-047),经过广泛的结构导向药物化学修饰,鉴定出 ZNL-05-044。生化评估和针对靶点结合的 NanoBRET 细胞测定的组合,指导 SAR 朝着具有显著改善的激酶组-wide 选择性的 2,4-二氨基噻唑 CDK11 探针方向发展,优于 JWD-047。ZNL-05-044 抑制 CDK11 导致 G2/M 细胞周期停滞,与先前评估 OTS964 的工作一致,并影响细胞中 CDK11 依赖性 mRNA 剪接。总之,ZNL-05-044 可用作进一步优化和研究 CDK11 抑制后果的工具化合物。